Mogrify to Present Preclinical Proof-of-Concept Data for First-in-Class Retinal In Vivo Reprogramming Therapy
Click to view quick news summary (Spoiler)
Mogrify plans to present preclinical evidence of preserved and restored visual function using direct retinal cell reprogramming.
CAMBRIDGE, England -- Mogrify Limited (Mogrify®), a regenerative medicine company developing a novel class of in vivo reprogramming therapies, today announced it will present preclinical proof-of-concept data at FLORetina-ICOOR 2026. The data support its first-in-class therapy designed to protect and regenerate the retina in patients with retinal disorders.
The company’s lead program uses transcription factor-mediated direct reprogramming to convert müller glial cells into functional photoreceptors within the retina. By addressing the photoreceptor loss underlying retinal degeneration, the approach aims to preserve and regenerate retinal function and restore clinically meaningful vision in patients with a range of retinal disorders.
In a recently completed large-scale preclinical proof-of-concept study, Mogrify demonstrated statistically significant preservation and restoration of visual function across multiple functional endpoints in a rodent model of induced retinal degeneration. The study used AAV-delivered combinations of transcription factors identified through the Company’s proprietary platform.
Mogrify’s platform combines next-generation sequencing and a human gene regulatory network-based approach to systematically and impartially identify optimal transcription factor combinations for controlling human cell fate. The technology enables direct in vivo conversion between any source cell type and any target cell type of clinical interest.
Chief Scientific Officer at Mogrify, Dr. Jonathan Appleby, will lead the program towards first-in-human studies, bringing 30 years of medicines development expertise. Mogrify is actively seeking partners to support the program's advancement.
Dr. Jonathan Appleby, Chief Scientific Officer, Mogrify, said: “We are thrilled to have generated statistically robust evidence that AAV delivery of MOGRIFY-identified transcription factor combinations can both protect against and reverse vision loss in a preclinical model of retinal degeneration. Demonstrated across several dosing formats and multiple functional endpoints, these findings represent an important step towards the development of a fundamentally novel and gene-agnostic approach to treating retinal disease.”
Joe Foster, Chief Executive Officer, Mogrify, added: “These results are an exciting milestone, providing a robust foundation for advancing our lead program towards clinical development. We are now exploring licensing and investment opportunities to progress this asset into first-in-human studies”
The presentation, Delivery of a selected combination of transcription factors can improve visual function in a preclinical model of retinal degeneration, will be given at the FLORetina-ICOOR 2026 Congress, taking place 3–6 December 2026.Presentation Track: IRD 1 – Natural History, Endpoints & Therapies. Presentation Date: Thursday, 3 December 2026--Presentation Time: 12:00–13:00. The data will also be presented as part of The Dolphin Tank, EYENOVATE’s premier ophthalmology and vision science innovation showcase, hosted during FLORetina-ICOOR 2026.
About Mogrify®
Mogrify® is a UK regenerative medicine company whose mission is to transform the lives of patients through a novel class of in vivo reprogramming therapies across otology, ophthalmology, diabetes, and other disease areas with a high unmet clinical need. The Company has developed a set of proprietary technologies that leverage transcriptomic and epigenetic sequencing combined with computational modeling to predict the factors required for direct cellular reprogramming and the maintenance of cell identity.
These platforms, for the first time, make it possible to both systematically enhance the efficiency of stem cell-derived forward programming and directly convert (transdifferentiate) mature cell types into other mature cell types (or states) without going through a pluripotent stem cell- or progenitor cell-state. Deployed directly in situ it is the latter uniquely positions the company to be able to generate cell types lost through disease or injury and potentially restore organ function directly inside the human body.
The platform is protected by the foundational patent application and a suite of additional patent applications covering improvements and extensions to the core platform and specific cell conversions. Uniquely positioned to address a regenerative medicine market estimated to be worth £120 billion GBP ($150 billion USD) by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications.
